trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Low dose naltrexone is an effective medical treatment

the verdict
CONTESTED
contested - the weight sits with the supporting side
Recorded sources
4 sources for · 3 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that low dose naltrexone is an effective medical treatment?

Partly. The effectiveness of low-dose naltrexone as a medical treatment is contested, with some reviews and studies suggesting potential benefits for chronic pain and inflammatory conditions, while recent meta-analyses and controlled trials indicate that its effects may not significantly outperform placebos or standard treatments, with high discontinuation rates.

Verdict: CONTESTED · 4 sources for, 3 against · Last checked

The analysis

The retrieved papers present mixed findings. Several reviews and observational reports (e.g., [0], [4], [9], [10]) highlight potential benefits, mechanisms, and off-label utility of low-dose naltrexone (LDN) for conditions like fibromyalgia and dermatologic disorders. Conversely, rigorous studies and meta-analyses challenge its effectiveness: a clinical trial ([3]) found LDN no better than placebo/standard treatment, a cohort study ([6]) noted high discontinuation rates due to lack of benefit despite a minor statistical change in scores, and a meta-analysis ([8]) concluded that LDN was not superior to placebo for fibromyalgia. Because high-quality syntheses and trials conflict with the positive clinical reports, the verdict is CONTESTED.

The evidence we hold leans leans supported

How this was weighed

official record 3x · fact-check 2x · hedged 1x · crowd & reference 1x

  • Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization · peer-reviewed · supports · weight 1.6 · 2018
  • A systematic literature review on the clinical efficacy of l · peer-reviewed · supports · weight 1.3 · 2023
  • Low-dose naltrexone for treatment of dermatologic conditions · peer-reviewed · supports · weight 1.05 · 2025
  • Therapeutic Uses and Efficacy of Low-Dose Naltrexone: A Scop · peer-reviewed · supports · weight 1.05 · 2025
  • The efficacy and safety of oral low dose naltrexone versus p · peer-reviewed · refutes · weight 1.3 · 2020
  • Efficacy and Safety of Low Dose Naltrexone for Chronic Pain · peer-reviewed · refutes · weight 1.05 · 2024
  • Efficacy of Low-Dose Naltrexone in Treating Patients with Fi · peer-reviewed · refutes · weight 1.05 · 2025
Evidence for · 4
Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization
2018
Reviews therapeutic utilization and notes clinical reports of possible benefits in various conditions.
Get citation
Toljan, K. & Vrooman, B. (2018). Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization. doi.org. https://doi.org/10.3390/medsci6040082

Evidence against · 3
The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial
2020
Randomized controlled trial found low-dose naltrexone failed to improve lichen planopilaris severity more than topical clobetasol alone.
Get citation
Lajevardi, V., Salarvand, F., Ghiasi, M., Nasimi, M., & Taraz, M. (2020). The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial. doi.org. https://doi.org/10.1080/09546634.2020.1774488

See more details
More for · 3
A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia
2023
Systematic review indicates some evidence that LDN reduces pain and increases quality of life in fibromyalgia.
Get citation
Partridge, S., Quadt, L., Bolton, M., Eccles, J., Thompson, C., Colasanti, A., Bremner, S., Jones, C. I., Bruun, K., & Marwijk, H. v. (2023). A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia. doi.org. https://doi.org/10.1016/j.heliyon.2023.e15638

Low-dose naltrexone for treatment of dermatologic conditions: a clinical review.
2025
Clinical review states LDN has demonstrated efficacy in treating various inflammatory dermatologic conditions.
Get citation
Zhou, M. H., Elston, D., Morrison, B. W., & Lipner, S. (2025). Low-dose naltrexone for treatment of dermatologic conditions: a clinical review.. doi.org. https://doi.org/10.1016/j.jaad.2025.09.028

Therapeutic Uses and Efficacy of Low-Dose Naltrexone: A Scoping Review.
2025
Scoping review synthesizes evidence showing clinical examples of LDN efficacy for a variety of medical conditions.
Get citation
KK, L. & RW, P. (2025). Therapeutic Uses and Efficacy of Low-Dose Naltrexone: A Scoping Review.. doi.org. https://doi.org/10.7759/cureus.81086

More against · 2
Efficacy and Safety of Low Dose Naltrexone for Chronic Pain
2024
Retrospective cohort study found that although LDN was associated with a statistically significant reduction in pain scores, over 75% of patients discontinued it due to lack of benefit.
Get citation
Irwin, M. N., Cooke, D. A., Berland, D., Marshall, V. D., & Smith, M. A. (2024). Efficacy and Safety of Low Dose Naltrexone for Chronic Pain. doi.org. https://doi.org/10.1080/15360288.2024.2302550

Efficacy of Low-Dose Naltrexone in Treating Patients with Fibromyalgia: systematic Review and Meta-Analysis
2025
Systematic review and meta-analysis found that while LDN reduced pain and symptoms from baseline, these effects were not superior to placebo.
Get citation
Ologunowa, A., Otoo, M. N., Caffrey, A., Buchanan, A., Eze, U. J., & Vyas, A. (2025). Efficacy of Low-Dose Naltrexone in Treating Patients with Fibromyalgia: systematic Review and Meta-Analysis. doi.org. https://doi.org/10.1080/15360288.2025.2496526

Related receipts

What does the evidence say?

The retrieved papers present mixed findings. Several reviews and observational reports (e.g., [0], [4], [9], [10]) highlight potential benefits, mechanisms, and off-label utility of low-dose naltrexone (LDN) for conditions like fibromyalgia and dermatologic disorders. Conversely, rigorous studies and meta-analyses challenge its effectiveness: a clinical trial ([3]) found LDN no better than placebo/standard treatment, a cohort study ([6]) noted high discontinuation rates due to lack of benefit despite a minor statistical change in scores, and a meta-analysis ([8]) concluded that LDN was not superior to placebo for fibromyalgia. Because high-quality syntheses and trials conflict with the positive clinical reports, the verdict is CONTESTED.

Receipt History
first checked05 Aug 2026
judged → CONTESTED · 3205 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work